Show simple item record

dc.contributor.authorMakówka, Agnieszka
dc.contributor.authorDryja, Przemysław
dc.contributor.authorChwatko, Grażyna
dc.contributor.authorBald, Edward
dc.contributor.authorNowicki, Michał
dc.identifier.citationMakówka et al.: Treatment of chronic hemodialysis patients with low-dose fenofibrate effectively reduces plasma lipids and affects plasma redox status. Lipids in Health and Disease 2012 11:47.pl_PL
dc.description.abstractDyslipidemia is common in chronic hemodialysis patients and its underlying mechanism is complex. Hemodialysis causes an imbalance between antioxidants and production of reactive oxygen species, which induces the oxidative stress and thereby may lead to accelerated atherosclerosis. Statins have been found to be little effective in end-stage kidney disease and other lipid-lowering therapies have been only scarcely studied. The study aimed to assess the effect of low-dose fenofibrate therapy on plasma lipids and redox status in long-term hemodialysis patients with mild hypertriglyceridemia. Twenty seven chronic hemodialysis patients without any lipid-lowering therapy were included in a double-blind crossover, placebo-controlled study. The patients were randomized into two groups and were given a sequence of either 100 mg of fenofibrate per each hemodialysis day for 4 weeks or placebo with a week-long wash-out period between treatment periods. Plasma lipids, high sensitive C-reactive protein (CRP), urea, creatinine, electrolytes, phosphocreatine kinase (CK), GOT, GPT and plasma thiols (total and free glutathione, homocysteine, cysteine and cysteinylglycine) were measured at baseline and after each of the study periods. Plasma aminothiols were measured by reversed phase HPLC with thiol derivatization with 2-chloro-1-methylquinolinium tetrafluoroborate. Fenofibrate therapy caused a significant decrease of total serum cholesterol, LDL cholesterol and triglycerides and an increase of HDL cholesterol. The treatment was well tolerated with no side-effects but there was a small but significant increase of CK not exceeding the upper limit of normal range. There were no changes of serum CRP, potassium, urea, and creatinine and liver enzymes during the treatment. Neither total nor total free cysteinylglycine and cysteine changed during the study but both total and free glutathione increased during the therapy with fenofibrate and the same was observed in case of plasma homocysteine. The study shows that a treatment with reduced fenofibrate dose is safe and effective in reducing serumtriglycerides and cholesterol in chronic dialysis patients and may shift plasma aminothiol balance towards a more antioxidative pattern.pl_PL
dc.publisherBioMed Centralpl_PL
dc.relation.ispartofseries(Lipids in Health and Disease;2012, 11
dc.rightsUznanie autorstwa-Użycie niekomercyjne-Bez utworów zależnych 3.0 Polska*
dc.subjectOxidative stresspl_PL
dc.titleTreatment of chronic hemodialysis patients with low-dose fenofibrate effectively reduces plasma lipids and affects plasma redox statuspl_PL
dc.contributor.authorAffiliationAgnieszka Makówka- Department of Nephrology, Hypertension and Kidney Transplantation, Medical University of Łódźpl_PL
dc.contributor.authorAffiliationPrzemysław Dryja, Department of Nephrology, Hypertension and Kidney Transplantation, Medical University of Łódźpl_PL
dc.contributor.authorAffiliationGrażyna Chwatko, Department of Environmental Chemistry, University of Łódźpl_PL
dc.contributor.authorAffiliationEdward Bald, Department of Environmental Chemistry, University of Łódźpl_PL
dc.contributor.authorAffiliationMichał Nowicki, Department of Nephrology, Hypertension and Kidney Transplantation, Medical University of Łódź, University Hospitapl_PL
dc.referencesAmann K, Tyralla K, Gross ML, Eifert T, Adamczak M, Ritz E: Special characteristics of atherosclerosis in chronic renal failure. Clin Nephrol 2003, 60(Suppl.1):S13–S21.pl_PL
dc.referencesDrüeke TB, Massy ZA: Atherosclerosis in CKD: differences from the general population. Nat Rev Nephrol 2010, 6:723–735.pl_PL
dc.referencesRoberts MA, Hare DL, Ratnaike S, Lerino FL: Cardiovascular biomarkers in CKD: pathophysiology and implications for clinical management of cardiac disease. Am J Kidney Dis 2006, 48:341–360.pl_PL
dc.referencesBadimon L, Torey RF, Vilahur G: Update on lipids, inflammation and atherothrombosis. Thromb Haemost 2011, 105(Suppl.1):S34–S42.pl_PL
dc.referencesKeech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d’Emden M, Whiting M, Ehnholm C, Laakso M, FIELD study investigators: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD Study): randomized controlled trial. Lancet 2005, 366:1849–1861.pl_PL
dc.referencesAnsquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G, DAIS Investigators: Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 2005, 45:485–493.pl_PL
dc.referencesWu J, Song Y, Li H, Chen J: Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report. Eur J Clin Pharmacol 2009, 65:1169–1174.pl_PL
dc.referencesAttridge RL, Linn WD, Ryan L, Koeller J, Frei CR: Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity. J Clin Lipidol 2012, 6:19–26.pl_PL
dc.referencesAnsquer JC, Dalton RN, Caussé E, Crimet D, Le Malicot K, Foucher C: Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people. Am J Kidney Dis 2008, 51:904–913.pl_PL
dc.referencesMolitch ME: Management of dyslipidemias in patients with diabetes and chronic kidney disease. Clin J Am Soc Nephrol 2006, 1:1090–1099.pl_PL
dc.referencesArora MK, Reddy K, Balakumar P: The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy. Eur J Pharmacol 2010, 636:137–144.pl_PL
dc.referencesHou X, Shen YH, Li C, Wang F, Zhang C, Bu P, Zhang Y: PPARalpha agonist fenofibrate protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress and MAPK activity. Biochem Biophys Res Commun 2010, 394:653–659.pl_PL
dc.referencesShin SJ, Lim JH, Chung S, Youn DY, Chung HW, Kim HW, Lee JH, Chang YS, Park CW: Peroxisome proliferator-activated receptor-alpha activator fenofibrate prevents high-fat diet-induced renal lipotoxicity in spontaneously hypertensive rats. Hypertens Res 2009, 32:835–845.pl_PL
dc.referencesLiang CC, Wang IK, Kuo HL, Yeh HC, Lin HH, Liu YL, Hsu WM, Huang CC, Chang CT: Long-term use of fenofibrate is associated with increased prevalence of gallstone disease among patients undergoing maintenance hemodialysis. Ren Fail 2011, 33:489–493.pl_PL
dc.referencesDesager JP, Costermans J, Verberckmoes R, Harvengt C: Effect of hemodialysis on plasma kinetics of fenofibrate in chronic renal failure. Nephron 1982, 31:51–54.pl_PL
dc.referencesHarvengt C, Desager JP: Pharmacokinetics of fenofibrate in man. Nouv Presse Med 1980, 49:3725–3737.pl_PL
dc.referencesPresse Med 1980, 49:3725–3737. 17. Okopień B, Haberka M, Madej A, Belowski D, Labuzek K, Krysiak R, Zieliński M, Basiak M, Herman ZS: Extralipid effects of micronized fenofibrate in dyslipidemic patients. Pharmacol Rep 2006, 58:729–735pl_PL
dc.referencesHimmelfarb J, McMenamin E, McMonagle E: Plasma aminothiol oxidation in chronic hemodialysis patients. Kidney Int 2002, 61:705–716pl_PL
dc.referencesBald E, Chwatko G, Głowacki R, Kuśmierek K: Analysis of plasma thiols by high-performance liquid chromatography with ultraviolet detection. J Chromatogr A 2004, 1032:109–115.pl_PL
dc.referencesYao Q, Pecoits-Filho R, Lindholm B, Stenvinkel P: Traditional and nontraditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease. Scand J Urol Nephrol 2004, 38:405–416pl_PL
dc.referencesYeun JY, Kaysen GA: C-reactive protein, oxidative stress, homocysteine, and troponin as inflammatory and metabolic predictors of atherosclerosis in ESRD. Curr Opin Nephrol Hypertens 2000, 9:621–630.pl_PL
dc.referencesKurnatowska I, Grzelak P, Stefańczyk L, Nowicki M: Tight relations between coronary calcification and atherosclerotic lesions in the carotid artery in chronic dialysis patients. Nephrology 2010, 15:184–189.pl_PL
dc.referencesKaysen GA: Biochemistry and biomarkers of inflamed patients: why look, what to assess. Clin J Am Soc Nephrol 2009, 4(Suppl.1):S56–S63.pl_PL
dc.referencesWu TJ, Ou HY, Chou CW, Hsiao SH, Lin CY, Kao PC: Decrease in inflammatory cardiovascular risk markers in hyperlipidemic diabetic patients treated with fenofibrate. Ann Clin Lab Sci 2007, 37:158–166pl_PL
dc.referencesHermans MP: Non-invited review: prevention of microvascular diabetic complications by fenofibrate: lessons from FIELD and ACCORD. Diab Vasc Dis Res 2011, 8:180–189.pl_PL
dc.referencesGenuth S, Ismail-Beigi F: Clinical Implications of the ACCORD Trial. J Clin Endocrinol Metab 2012, 97:41–48.pl_PL
dc.referencesWatanabe H, Miyamoto Y, Otagiri M, Maruyama T: Update on the pharmacokinetics and redox properties of protein-bound uremic toxins. J Pharm Sci 2011, 100:3682–3695.pl_PL
dc.referencesBostom AG, Shemin D, Verhoef P, Nadeau MR, Jacques PF, Selhub J, Dworkin L, Rosenberg IH: Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients: A prospective study. Arteriosclerosis Thromb Vasc Biol 1997, 17:2554–2558.pl_PL
dc.referencesSuliman ME, Divino-Filho JC, Barany P, Anderstam B, Lindholm B, Bergström J: Effects of high-dose folic acid and pyridoxine on plasma and erythrocyte sulfur amino acids in hemodialysis patients. J Am Soc Nephrol 1999, 10:1287–1296.pl_PL
dc.referencesCaussé E, Ribes D, Longlune N, Kamar N, Durand D, Salvayre R, Rostaing L: Aminothiols and allantoin in chronic dialysis patients: effects of hemodialysis sessions. Clin Nephrol 2010, 73:51–57.pl_PL
dc.referencesSauls DL, Arnold EK, Bell CW, Allen JC, Hoffman M: Pro-thrombotic and pro-oxidant effects of diet-induced hyperhomocysteinemia. Thromb Res 2007, 120:117–126pl_PL
dc.referencesHofmann MA, Lalla E, Lu Y: Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest 2001, 107:675–683.pl_PL
dc.referencesGraham LM, Daly LE, Refsum HM, Robinson K, Brattström LE, Ueland PM, Palma-Reis RJ, Boers GH, Sheahan RG, Israelsson B, Uiterwaal CS, Meleady R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht JC, de Valk HW, Sales Lúis AC, Parrot-Rouland FM, Tan KS, Higgins I, Garcon D, Andria G: Plasma homocysteine as a risk factor for vascular disease: The European Concerted Action Project. JAMA 1997, 277:1775–1781.pl_PL
dc.referencesBoushey CJ, Beresford SA, Omenn GS, Motulsky AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995, 274:1049–1057.pl_PL
dc.referencesKugiyama K, Ohgushi M, Motoyama T, Hirashima O, Soejima H, Misumi K, Yoshimura M, Ogawa H, Sugiyama S, Yasue H: Intracoronary infusion of reduced glutathione improves endothelial vasomotor response to acetylcholine in human coronary circulation. Circulation 1998, 97:2299– 2301.pl_PL
dc.referencesMorrison JA, Jacobsen DW, Sprecher DL, Robinson K, Khoury P, Daniels SR: Serum glutathione in adolescent males predicts parental coronary heart disease. Circulation 1999, 100:2244–2247.pl_PL
dc.referencesLapenna D, de Gioia S, Ciofani G, Mezzetti A, Ucchino S, Calafiore AM, Napolitano AM, Di Ilio C, Cuccurullo F: Glutathione-related antioxidant defenses in human atherosclerotic plaques. Circulation 1998, 97:1930– 1934.pl_PL
dc.referencesUeland PM, Mansoor MA, Guttormsen AB, Müller F, Aukrust P, Refsum H, Svardal AM: Reduced, oxidized and protein-bound forms of homocysteine and other aminothiols in plasma comprise the redox thiol status–a possible element of the extracellular antioxidant defense system. J Nutr 1996, 126(4 Suppl):1281S–1284S.pl_PL
dc.referencesKasiske BL: Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis 1998, 32:S142–S156.pl_PL
dc.referencesBrunzell JD, Albers JJ, Haas LB, Goldberg AP, Agadoa L, Sherrard DJ: Prevalence of serum lipid abnormalities in chronic hemodialysis. Metabolism 1977, 26:903–910pl_PL
dc.referencesAttman PO, Samuelsson O: Dyslipidemia of kidney disease. Curr Opin Lipidol 2009, 20:293–299.pl_PL
dc.referencesChauhan V, Vaid M: Dyslipidemia in chronic kidney disease: managing a high-risk combination. Postgrad Med 2009, 121:54–61.pl_PL
dc.referencesRitz E, Nowicki M, Więcek A: Organ and metabolic complications: Lipids/ atherosclerosis. In Replacement of renal function by dialysis. Edition 4. Edited by Jacobs C, Kjellstrand CM, Koch KM, Winchester JF. The Netherlands: Kluwer Academic Publishers; 1996:1003–1013.pl_PL
dc.referencesTing RD, Keech AC, Drury PL, Donoghoe MW, Hedley J, Jenkins AJ, Davis TM, Lehto S, Celermajer D, Simes RJ, Rajamani K, Stanton K: on behalf of the FIELD Study Investigators. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: The FIELD Study. Diabetes Care 2012, 35:218–225pl_PL
dc.referencesKalaitzidis RG, Elisaf MS: The role of statins in chronic kidney disease. Am J Nephrol 2011, 34:195–202.pl_PL
dc.referencesEpstein M, Vaziri ND: Statins in the management of dyslipidemia associated with chronic kidney disease. Nat Rev Nephrol 2012, 8:214–223.pl_PL

Files in this item


This item appears in the following Collection(s)

Show simple item record

Uznanie autorstwa-Użycie niekomercyjne-Bez utworów zależnych 3.0 Polska
Except where otherwise noted, this item's license is described as Uznanie autorstwa-Użycie niekomercyjne-Bez utworów zależnych 3.0 Polska